Moderna (MRNA) PT Raised to $43 at Oppenheimer; 'COVID-19 Vaccine Potential Taking Shape'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Moderna (MRNA) PT Raised to $43 at Oppenheimer; 'COVID-19 Vaccine Potential Taking Shape'

Moderna (MRNA) Highlights Opportunity of mRNA Vaccines at its First Vaccines Day

April 14, 2020 7:03 AM EDT

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today is hosting its first Vaccines Day, including presentations highlighting the potential advantages of mRNA vaccines. The Company is also announcing new positive interim Phase 1 data from its Zika vaccine candidate (mRNA-1893). With this data, Modernas prophylactic vaccines modality now has seven positive Phase 1 readouts, including a combination vaccine against two viruses (hMPV and PIV3; mRNA-1653). The Company has demonstrated neutralizing immunogenicity against all eight viruses... More